



ASX Announcement

26 May 2026

2026 Annual General Meeting Results

Melbourne, Australia, 26 May 2026 – In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001 (Cth)*, Avecho Biotechnology Limited (ASX: AVE) advises that the details of the resolutions and the proxies received in respect of each resolution at its Annual General Meeting today are set out in the attached proxy summary.

For enquiries, please contact

Naomi Lawrie
Company Secretary
+61 1300 384 692

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

About Avecho

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's lead asset is a proprietary cannabidiol ("CBD") TPM soft-gel capsule demonstrated to increase CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for the treatment of insomnia.

See more here - avecho.com.au

For personal use only

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	1,187,473,648 96.74%	26,869,297 2.19%	13,179,918 1.07%	3,513,727	1,240,030,875 97.88%	26,869,297 2.12%	3,513,727	Carried
2 Re-Election of Mr Matthew Patrick McNamara as a Director of the Company	Ordinary	This resolution was withdrawn				This resolution was withdrawn			Withdrawn
3 Renewal of Avecho Biotechnology Limited Equity Incentive Plan	Ordinary	1,188,484,836 96.80%	26,096,665 2.13%	13,178,807 1.07%	19,793,789	1,240,840,952 97.92%	26,296,665 2.08%	19,793,789	Carried
4 Ratification of prior Issue of 182,653,633 Shares under Placement	Ordinary	1,103,464,777 96.75%	23,726,771 2.08%	13,363,807 1.17%	3,832,075	1,179,095,558 98.02%	23,803,771 1.98%	3,832,075	Carried
5 Ratification of prior Issue of 20,000,000 Options to the Lead Manager (or its nominee)	Ordinary	1,139,016,466 95.77%	36,970,098 3.11%	13,363,807 1.12%	64,037,059	1,214,524,247 97.03%	37,170,098 2.97%	64,037,059	Carried
6 Approval of 10% Placement Facility	Special	1,211,907,522 97.03%	23,746,128 1.90%	13,363,807 1.07%	4,369,973	1,287,415,303 98.17%	23,946,128 1.83%	4,369,973	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Resolution	Reasons(s) for not putting resolution to the meeting
2 Re-Election of Mr Matthew Patrick McNamara as a Director of the Company	Refer to ASX Announcement dated 25 May 2026